Long-term protective potency of AAV vector-based SARS-CoV-2 prophylaxis in mice and non-human primates - Summary - MDSpire

Long-term protective potency of AAV vector-based SARS-CoV-2 prophylaxis in mice and non-human primates

  • By

  • Ekaterina I. Ryabova

  • Artem A. Derkaev

  • Ilias B. Esmagambetov

  • Mikhail A. Dovgiy

  • Ilya V. Gordeychuk

  • Inna V. Shuliakova

  • Rosa M. Hossain

  • Anton A. Blinov

  • Anna A. Iliukhina

  • Daria M. Grousova

  • Ilya D. Zorkov

  • Daria V. Avdoshina

  • Stanislav A. Gulyaev

  • Vasiliy D. Apolokhov

  • Tatiana V. Gulyaeva

  • Irina A. Favorskaya

  • Dmitry V. Shcheblyakov

  • Alexander L. Gintsburg

  • Denis Y. Logunov

  • June 4, 2026

  • 0 min

Share

Objective:

To evaluate the long-term expression, pharmacokinetics, immunogenicity, biodistribution, and protective efficacy of an rAAV vector encoding the single-domain antibody P2C5-Fc against SARS-CoV-2.

Key Findings:
  • Rapid antibody detection in serum peaked by approximately 120 days and remained protective for over 480 days in mice and up to 1,120 days in marmosets.
  • Neutralizing titers correlated with serum P2C5-Fc concentrations, providing complete protection against lethal SARS-CoV-2 challenges.
  • Biodistribution showed predominant localization at the injection site and regional lymph nodes with minimal off-target spread.
  • Moderate anti-AAV capsid antibody responses were detected, while anti-drug antibodies against P2C5-Fc were undetectable.
Interpretation:

Limitations:
  • The study was conducted in preclinical models, which may not fully replicate human responses.
  • Long-term safety and efficacy in humans remain to be established.
Conclusion:

Original Source(s)

Long-term protective potency of AAV vector-based SARS-CoV-2 prophylaxis in mice and non-human primates

  • by Ekaterina I. Ryabova, Artem A. Derkaev, Ilias B. Esmagambetov, Mikhail A. Dovgiy, Ilya V. Gordeychuk, Inna V. Shuliakova, Rosa M. Hossain, Anton A. Blinov, Anna A. Iliukhina, Daria M. Grousova, Ilya D. Zorkov, Daria V. Avdoshina, Stanislav A. Gulyaev, Vasiliy D. Apolokhov, Tatiana V. Gulyaeva, Irina A. Favorskaya, Dmitry V. Shcheblyakov, Alexander L. Gintsburg, Denis Y. Logunov

  • June 4, 2026

Related Content

Epidemiological characteristics of childhood infectious diseases at Qingyang maternal and child health care hospital during the COVID-19 pandemic and the post-pandemic period

CDC says containing the spread of Ebola is top priority

The Amish way of health care